08:00 , Jan 19, 2009 |  BC Week In Review  |  Company News

AuricX Pharmaceuticals, SRI International deal

AuricX received exclusive, worldwide rights to develop and commercialize SRI's preclinical oral formulation of vancomycin to treat methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant S. epidermis (MRSE), and hospital- and community-acquired infections. The not-for-profit received undisclosed upfront...